Author: Vikas Kumar
16 July 2022
The Global Intravenous Immunoglobulin Market is expected to grow significantly by 2027 expanding at a reasonable CAGR of around 7% during the forecast period (2021-2027). Glycoprotein molecules that are manufactured by the plasma or the white blood cells are known as immunoglobulins. These immunoglobulins that are administered through the intravenous route are intravenous immunoglobulins.
For a detailed analysis of the intravenous immunoglobulin browse through https://univdatos.com/report/intravenous-immunoglobulin-market/
The global intravenous immunoglobulin market is anticipated to witness an uptick with the development of social society leading to changes in diet and other lifestyles. This along with the rapidly growing aging population across the globe is causing an increase in the number of patients having primary immunodeficiency and other rare immunological disorders. For instance, more than 500,000 persons in the United States suffer from more than 200 distinct types of primary immunodeficiency diseases (PIDs), as per the NIH data. Also, according to the U.S. National Library of Medicine and National Institute of Health, nearly 6 million patients are suffering from PID worldwide. Furthermore, increased investment in the healthcare industry and growing adoption of immunoglobin with product launches and approvals are also some other factors contributing to the growth of the market globally.
Based on the product, the intravenous immunoglobulin market is segmented into IgG, IgE, IgA, IgD, and IgM. The IgG segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe as it is the most common antibody (75% to 80%) of all antibodies present in our body that are required for fighting various viral and bacterial infections.
For a detailed analysis of the products of intravenous immunoglobulin browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=22667
Based on application, the intravenous immunoglobulin market is divided into hypogammaglobulinemia, CIDP, myasthenia gravis, Guillain-barre syndrome, immunodeficiency diseases, and others. The hypogammaglobulinemia segment occupied the major share of the intravenous immunoglobulin market in 2020 and it is expected to grow with a substantial CAGR in the upcoming years as it is one of the most common primary immunodeficiency which encompasses a majority of immune-compromised patients. However, the CIDP segment is also expected to grow considerably during the upcoming years.
Additionally, the report provides detailed report also provides insights into the global intravenous immunoglobulin market according to the regions such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, India, Australia, Japan, and Rest of APAC), Rest of World has been conducted. North America dominated the market in 2020 owing to the well-established market players and increasing geriatric population.
Biotest AG, Baxter International Inc., Octapharma AG, China Biologic Products, Inc., CSL Behring LLC, Grifols S.A., Kedrion S.p.A., Pfizer Inc., LFB Biomedicaments S.A., Baxalta, are some of the key players operating in the global intravenous immunoglobulin market. Several M&As along with partnerships have been undertaken by these players to develop new products.
Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=22667
Global Intravenous Immunoglobulin Market Segmentation
Market Insight, by Type
Market Insight, by Application
Market Insight, by End-Users
Market Insight, by Region
Top Company Profiles
Get a call back